Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Myeloma High Impact Factor Journals

Multiple Myeloma (MM) is the second most common cancer of the blood and accounts for 1% of all malignancies. MM is a very heterogeneous disease from both clinical and molecular point of view. Its pathogenesis remains poorly understood and it is considered an incurable disease. The molecular epidemiology of MM is an exciting area of research. Major advances have been made in recent years highlighting the need to face the disease through common efforts within large cooperative groups. Multiple Myeloma is a progressive and debilitating B-cell disorder typified by the accumulation and dissemination of malignant plasma cells in the bone marrow which subsequently induce osteolytic lesions. Despite recent advancement of new therapies for MM, patients ultimately develop drug resistance and succumb to the disease. High-impact journals are those considered to be highly influential in their respective fields. The impact factor of journal provides quantitative assessment tool for grading, evaluating, sorting and comparing journals of similar kind. It reflects the average number of citations to recent articles published in science and social science journals in a particular year or period, and is frequently used as a proxy for the relative importance of a journal within its field. It is first devised by Eugene Garfield, the founder of the Institute for Scientific Information. The impact factor of a journal is evaluated by dividing the number of current year citations to the source items published in that journal during the previous two years.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on September, 2024

Top